文献速递艾滋病与性传播感染

比克替拉韦在生殖道和直肠的分布及HIV-1 RNA衰减动力学

Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项前瞻性多中心研究纳入23例未治HIV-1成人,启动比克替拉韦/恩曲他滨/丙酚替诺福韦后,精浆和直肠液中HIV-1 RNA快速下降,女性宫颈阴道液第14天均检测不到。第28天和12周时,精浆、直肠组织、宫颈阴道液中总比克替拉韦浓度分别为血浆的2.7%、2.6%、2.8%,游离部分占42.6%–51.1%,均远高于EC50(1.1 ng/mL)。

要点

  • 精浆和直肠液中HIV-1 RNA下降速度及检测不到的时间均快于血浆。
  • 女性宫颈阴道液HIV-1 RNA第14天全部检测不到。
  • 精浆、直肠组织、宫颈阴道液中游离比克替拉韦浓度高度超过EC50。

核心结论

  • 比克替拉韦/恩曲他滨/丙酚替诺福韦使生殖道和直肠液中HIV-1 RNA快速衰减。
  • 精浆、直肠组织和宫颈阴道液中游离比克替拉韦浓度远高于EC50(1.1 ng/mL)。

研究设计与样本

  • 前瞻性多中心研究,纳入15例男性和8例女性未治HIV-1成人,启动比克替拉韦/恩曲他滨/丙酚替诺福韦。
  • 在基线、第3、7、14、28天及第12、24周检测血浆、精浆、直肠液和宫颈阴道液HIV-1 RNA(定量下限40 copies/mL)。
  • 第28天和第12周用经验证的液相色谱-串联质谱法测定血浆、精浆、宫颈阴道液和直肠组织中总及蛋白未结合比克替拉韦24小时谷浓度。

主要发现

  • 精浆、直肠液、宫颈阴道液基线HIV-1 RNA>40 copies/mL者分别为12/15、13/15、4/8,中位数分别为3.54(2.41–3.79)、4.19(2.98–4.70)、2.56(1.61–3.56)log10 copies/mL。
  • 精浆初始衰减斜率显著低于直肠液和血浆;精浆和直肠液HIV-1 RNA检测不到的时间显著短于血浆。
  • 所有女性第14天宫颈阴道液HIV-1 RNA均检测不到。
  • 精浆、直肠组织、宫颈阴道液总比克替拉韦中位数分别为65.5(20.1–923)ng/mL、74.1(6.0–478.5)ng/g、61.6(14.4–1760.2)ng/mL,分别为血浆浓度的2.7%、2.6%、2.8%。
  • 精浆、直肠组织、宫颈阴道液蛋白未结合比克替拉韦比例分别为51.1%、44.6%、42.6%。

关键数值与推荐

  • 精浆、直肠组织、宫颈阴道液总比克替拉韦浓度分别为血浆的2.7%、2.6%、2.8%。
  • 蛋白未结合比克替拉韦在精浆、直肠组织、宫颈阴道液分别为51.1%、44.6%、42.6%。
  • 比克替拉韦EC50为1.1 ng/mL,各部位游离浓度均高度超过该值。

临床怎么用

  • 支持比克替拉韦/恩曲他滨/丙酚替诺福韦在生殖道和直肠部位快速抑制HIV-1 RNA。
  • 精浆和直肠液病毒衰减快于血浆,提示这些部位暴露于有效药物浓度。

局限性

  • 样本量小(15例男性、8例女性)。
  • 仅评估比克替拉韦/恩曲他滨/丙酚替诺福韦方案,随访至24周。
  • 未报告临床结局,仅报告病毒学和药代动力学指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pharmacokinetics of bictegravir (BIC) and its association with the decay of human immunodeficiency virus (HIV)-1 RNA in genital fluids and the rectum have not yet been addressed. METHODS: We conducted a prospective, multicenter study of antiretroviral-naive people living with HIV-1 and initiating BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF). HIV-1 RNA was measured (limit of quantification, 40 copies/mL) in blood plasma (BP), seminal plasma (SP), rectal fluid (RF), and cervicovaginal fluid (CVF) at baseline; Days 3, 7, 14, and 28; and Weeks 12 and 24. Total and protein-unbound BIC concentrations at 24 hours postdose (C24h) were quantified in BP, SP, CVF and rectal tissue (RT) on Day 28 and Week 12 using a validated liquid chromatography-tandem mass spectrometry assay. RESULTS: The study population comprised 15 males and 8 females. In SP, RF, and CVF, the baseline HIV-1 RNA was >40 copies/mL in 12/15, 13/15, and 4/8 individuals, respectively, with medians of 3.54 (2.41-3.79), 4.19 (2.98-4.70), and 2.56 (1.61-3.56) log10 copies/mL, respectively. The initial decay slope was significantly lower in SP than in RF and BP. The time to undetectable HIV-1 RNA was significantly shorter in SP and RF than in BP. All women achieved undetectable HIV-1 RNA in CVF at Day 14. The median total BIC concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, respectively, representing 2.7%, 2.6%, and 2.8% of the BP concentration, respectively, while the protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively. CONCLUSIONS: BIC/FTC/TAF led to rapid decay of HIV-1 RNA in genital and rectal fluids. Protein-unbound BIC concentrations in SP, RT, and CVF highly exceeded the half-maximal effective concentration (EC50) value (1.1 ng/mL). CLINICAL TRIALS REGISTRATION: EudraCT 2018-002310-12.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Imaz A, Tiraboschi JM, Niubó J, et al. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clin Infect Dis. 2021. PMID: 32945851. doi:10.1093/cid/ciaa1416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。